The new Covid vaccine has been approved, why you might not want to rush out to get it yet

by Arthur Allen and Eliza Fawcett, Healthbeat
Rebecca Grapevine, Healthbeat

Because viruses evolve as they infect people, the CDC has recommended updated covid vaccines each year.

The FDA has approved an updated covid shot for everyone 6 months old and up, which renews a now-annual quandary for Americans: Get the shot now, with the latest covid outbreak sweeping the country, or hold it in reserve for the winter wave?

The new vaccine should provide some protection to everyone. But many healthy people who have already been vaccinated or have immunity because they’ve been exposed to covid enough times may want to wait a few months.

Covid has become commonplace. For some, it’s a minor illness with few symptoms. Others are laid up with fever, cough, and fatigue for days or weeks. A much smaller group — mostly older or chronically ill people — suffer hospitalization or death.

It’s important for those in high-risk groups to get vaccinated, but vaccine protection wanes after a few months. Those who run to get the new vaccine may be more likely to fall ill this winter when the next wave hits, said William Schaffner, an infectious disease professor at Vanderbilt University School of Medicine and a spokesperson for the National Foundation for Infectious Diseases.

On the other hand, by late fall the major variants may have changed, rendering the vaccine less effective, said Peter Marks, the FDA’s top vaccine official, at a briefing Aug. 23. He urged everyone eligible to get immunized, noting that the risk of long covid is greater in the un- and undervaccinated.

Of course, if last year’s covid vaccine rollout is any guide, few Americans will heed his advice, even though this summer’s surge has been unusually intense, with levels of the covid virus in wastewater suggesting infections are as widespread as they were in the winter.

The Centers for Disease Control and Prevention now looks to wastewater as fewer people are reporting test results to health authorities. The wastewater data shows the epidemic is worst in Western and Southern states. In New York, for example, levels are considered “high” — compared with “very high” in Georgia.

Hospitalizations and deaths due to covid have trended up, too. But unlike infections, these rates are nowhere near those seen in winter surges, or in summers past. More than 2,000 people died of covid in July — a high number but a small fraction of the at least 25,700 covid deaths in July 2020.

Partial immunity built up through vaccines and prior infections deserves credit for this relief. A new study suggests that current variants may be less virulent — in the study, one of the recent variants did not kill mice exposed to it, unlike most earlier covid variants.

Covid rapid tests will no longer be free

Alexandra Koch/Pixabay

Public health officials note that even with more cases this summer, people seem to be managing their sickness at home. “We did see a little rise in the number of cases, but it didn’t have a significant impact in terms of hospitalizations and emergency room visits,” said Manisha Juthani, public health commissioner of Connecticut, at a news briefing Aug. 21.

Unlike influenza or traditional cold viruses, covid seems to thrive outside the cold months, when germy schoolkids, dry air, and indoor activities are thought to enable the spread of air- and saliva-borne viruses. No one is exactly sure why.

“Covid is still very transmissible, very new, and people congregate inside in air-conditioned rooms during the summer,” said John Moore, a virologist and professor at Cornell University’s Weill Cornell Medicine College.

Or “maybe covid is more tolerant of humidity or other environmental conditions in the summer,” said Caitlin Rivers, an epidemiologist at Johns Hopkins University.

Because viruses evolve as they infect people, the CDC has recommended updated covid vaccines each year. Last fall’s booster was designed to target the omicron variant circulating in 2023. This year, mRNA vaccines made by Moderna and Pfizer and the protein-based vaccine from Novavax — which has yet to be approved by the FDA — target a more recent omicron variant, JN.1.

The FDA determined that the mRNA vaccines strongly protected people from severe disease and death — and would do so even though earlier variants of JN.1 are now being overtaken by others.

Public interest in covid vaccines has waned, with only 1 in 5 adults getting vaccinated since last September, compared with about 80% who got the first dose. New Yorkers have been slightly above the national vaccination rate, while in Georgia only about 17% got the latest shot.

Vaccine uptake is lower in states where the majority voted for Donald Trump in 2020 and among those who have less money and education, less health care access, or less time off from work. These groups are also more likely to be hospitalized or die of the disease, according to a 2023 study in The Lancet.

While the newly formulated vaccines are better targeted at the circulating covid variants, uninsured and underinsured Americans may have to rush if they hope to get one for free. A CDC program that provided boosters to 1.5 million people over the last year ran out of money and is ending Aug. 31.

The agency drummed up $62 million in unspent funds to pay state and local health departments to provide the new shots to those not covered by insurance. But “that may not go very far” if the vaccine costs the agency around $86 a dose, as it did last year, said Kelly Moore, CEO of Immunize.org, which advocates for vaccination.

People who pay out-of-pocket at pharmacies face higher prices: CVS plans to sell the updated vaccine for $201.99, said Amy Thibault, a spokesperson for the company.

“Price can be a barrier, access can be a barrier” to vaccination, said David Scales, an assistant professor of medicine at Weill Cornell Medical College.

Without an access program that provides vaccines to uninsured adults, “we’ll see disparities in health outcomes and disproportionate outbreaks in the working poor, who can ill afford to take off work,” Kelly Moore said.

New York state has about $1 million to fill the gaps when the CDC’s program ends, said Danielle De Souza, a spokesperson for the New York State Department of Health. That will buy around 12,500 doses for uninsured and underinsured adults, she said. There are roughly one million uninsured people in the state.

CDC and FDA experts last year decided to promote annual fall vaccination against covid and influenza along with a one-time respiratory syncytial virus shot for some groups.

It would be impractical for the vaccine-makers to change the covid vaccine’s recipe twice every year, and offering the three vaccines during one or two health care visits appears to be the best way to increase uptake of all of them, said Schaffner, who consults for the CDC’s policy-setting Advisory Committee on Immunization Practices.

At its next meeting, in October, the committee is likely to urge vulnerable people to get a second dose of the same covid vaccine in the spring, for protection against the next summer wave, he said.

If you’re in a vulnerable population and waiting to get vaccinated until closer to the holiday season, Schaffner said, it makes sense to wear a mask and avoid big crowds, and to get a test if you think you have covid. If positive, people in these groups should seek medical attention since the antiviral pill Paxlovid might ameliorate their symptoms and keep them out of the hospital.

As for conscientious others who feel they may be sick and don’t want to spread the covid virus, the best advice is to get a single test and, if positive, try to isolate for a few days and then wear a mask for several days while avoiding crowded rooms. Repeat testing after a positive result is pointless, since viral particles in the nose may remain for days without signifying a risk of infecting others, Schaffner said.

The Health and Human Services Department is making four free covid tests available to anyone who requests them starting in late September through covidtest.gov, said Dawn O’Connell, assistant secretary for preparedness and response, at the Aug. 23 briefing.

The government is focusing its fall vaccine advocacy campaign, which it’s calling “Risk less, live more,” on older people and nursing home residents, said HHS spokesperson Jeff Nesbit.

Not everyone may really need a fall covid booster, but “it’s not wrong to give people options,” John Moore said. “The 20-year-old athlete is less at risk than the 70-year-old overweight dude. It’s as simple as that.”

KFF Health News correspondent Amy Maxmen contributed to this report.

Healthbeat is a nonprofit newsroom covering public health published by Civic News Company and KFF Health News. Sign up for their newsletters here.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News' free Morning Briefing.

Updated COVID-19 vaccine approved by FDA coming soon

by Matt Sheehan
OSF Healthcare

Photo provided
Dr. Doug Kasper
PEORIA - The fall virus season is upon us, and the U.S. Food & Drug Administration just approved one of the newest tools to protect Americans from severe illness.

The updated COVID-19 vaccine is expected to be available at pharmacies around the country in the coming weeks.

The mRNA vaccine is not a booster, says Doug Kasper, MD, an infectious disease specialist with OSF HealthCare. He says it’s recommended for a much broader portion of the population.

"The vaccine is now recommended for everybody 6 months and older as a one-time, once-a-year vaccine," Dr. Kasper says. “The vaccine has been updated. For people who are at really high risk, those 65 and older or with respiratory conditions, they may get a second shot. This would be in a six-month interval in the springtime.”

Does the vaccine prevent me from getting COVID-19?
The quick answer? No, much like you find with the annual influenza vaccine.

"The vaccine seeks to protect severe outcomes associated with COVID-19. It doesn't protect you from getting COVID, it tries to decrease the severity of how sick you would get," Dr. Kasper says.

While there has been an uptick in COVID-19 cases recently, Dr. Kasper says there has not been an increase in COVID hospitalizations. He attributes this to robust natural immunity in the population and adding this COVID-19 vaccine is just another way to protect yourself from severe illness.

FDA’s “What to Know” sheet
The 2024-2025 formula has been updated to protect against the Omicron variant KP.2.

  • Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated, authorized Pfizer-BioNTech COVID-19 vaccine or two doses of the updated, authorized Moderna COVID-19 vaccine.
  • Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines (timing and number of doses to administer depends on the previous COVID-19 vaccine received).
  • Individuals 5 years through 11 years of age regardless of previous vaccination are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least two months after the last dose of any COVID-19 vaccine.
  • Individuals 12 years of age and older are eligible to receive a single dose of the updated, approved Comirnaty (manufactured by Pfizer BioNTech) or the updated, approved Spikevax (manufactured by Moderna); if previously vaccinated, the dose is administered at least two months since the last dose of any COVID-19 vaccine.
  • Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years of age as described in the Moderna COVID-19 vaccine and Pfizer-BioNTech COVID-19 vaccine fact sheets.
Commercial retailers are the way to go
As the vaccines from Pfizer and Moderna become available, the Centers for Disease Control & Prevention (CDC) will publish a pharmacy lookup website at https://www.vaccines.gov/en/vaccines.gov to help people find the nearest vaccine locations.

Dr. Kasper says the best bet at getting a vaccine appointment for COVID-19 or influenza, is through pharmacies at local commercial retailers like Target, Walgreens, CVS or Walmart.

Free COVID-19 home tests are coming back
“The U.S. government will make the at-home COVID testing available for free again this year. You can request up to four home tests that will be delivered to your address for free,” Dr. Kasper says. That gives people another option for testing if they think they're developing signs of COVID even after receiving a vaccine, which can be another way to avoid wait lines at urgent cares, ERs or primary care clinics, and to keep themselves isolated until symptoms have resolved.”

The U.S. Department of Health & Human Services reports that COVIDTests.gov will be the website to order from once the website is active.

Status of the Novavax vaccine
A third manufacturer, Novavax, makes a protein-based vaccine similar to influenza vaccines. While it hasn’t been approved by the FDA, Dr. Kasper suspects it will be soon.

"It likely will be approved, and Novavax has been a prior manufacturer of COVID-19 vaccines. That is a third option that will be coming that isn't mRNA based for people to consider if they had an adverse reaction with Pfizer or Moderna in the past,” Dr. Kasper says.

Can I get the COVID-19 and flu vaccine at the same time?
"There's no issue with timing on getting the COVID and influenza vaccines. The RSV vaccine is recommended to be given separate," Dr. Kasper says. “Most of that has to do with the fact they weren't studied together, there's not an adverse issue with it. For the population, COVID and influenza are recommended across almost all age groups. RSV is for our older population, so we recommend spacing that out by a week or two.”

For all vaccine questions, Dr. Kasper recommends speaking with your primary care team to review your options.


Read our latest health and medical news

Don't have health insurance for an updated COVID-19 vaccine? Here's how to get one free

BrandPoint - While COVID-19 activity is still below the levels seen last year at this time, COVID-19 hospitalizations are rising quickly. There is still time to get yourself and your loved ones vaccinated. Getting an updated COVID-19 vaccine is the best way to stay protected against serious illness from COVID-19. The Centers for Disease Control and Prevention (CDC) recommends that everyone 6 months and older stay up to date with COVID-19 vaccination. Vaccination also lowers your risk of getting long COVID - a wide range of health problems that can last weeks, months or even years after COVID-19 infection.

Most adults can get a free updated COVID-19 vaccine through their private health insurance, Medicare or Medicaid plans. However, some health insurance plans don't fully cover the cost of a COVID-19 vaccine, and an estimated 25-30 million people living in the U.S. don't have health insurance.

To address this concern, CDC's Bridge Access Program is offering adults who are uninsured or whose insurance doesn't fully cover COVID-19 vaccination a free, updated COVID-19 vaccine. This program will end by Dec. 31, 2024. To date, more than a million COVID-19 vaccine doses have been provided through the program.

Bridge Access Program

There is no enrollment process or application to qualify, and you don't need to provide identification or proof of insurance to get a vaccine through the Bridge Access Program. If you are 18 years or older and don't have health insurance, or your plan doesn't fully cover an updated COVID-19 vaccine, the Bridge Access Program can provide one for free at participating CVS, Walgreens and eTrueNorth-partnering pharmacies, local health centers and health providers.

How to find a vaccine through the Bridge Access Program

Follow these steps to find pharmacies and health care providers participating in the Bridge Access Program near you:

* Visit Vaccines.gov.

* Select "Find COVID-19 Vaccines."

* Enter your 5-digit ZIP code in the search bar and select which vaccine option(s) you're interested in finding.

* Select "Search for COVID-19 Vaccines."

* Select the option "Bridge Access Program Participant" to show participating providers and pharmacies.

When you find a convenient location, call ahead to confirm that they can provide you with a free updated COVID-19 vaccine through the Bridge Access Program. If you can't find a participating pharmacy or provider near you, check back later because new locations are still being added.

Why get vaccinated now?

Viruses constantly change through mutation and sometimes these mutations result in a new strain (or variant) of the virus. It's important to know that the updated COVID-19 vaccines offer protection against the variants spreading throughout our communities right now.

The cold winter months are a time when people spend more time in crowded indoor settings, where respiratory viruses, including COVID-19, may be more readily transmitted. Getting an updated COVID-19 vaccine will help protect you from serious illness.

Don't let cost stop you from getting an updated COVID-19 vaccine this year. Free COVID-19 vaccines are still available. If you are uninsured or your plan won't fully cover it, visit Vaccines.gov today to find a Bridge Access Program provider near you.


Health experts say it is okay to get your flu and COVID shots at the same time

Lee Batsakis
OSF Healthcare

EVERGREEN PARK -- It happens every year: flu season, which typically peaks between December and February. This year will mark the third flu season with another virus also circulating: COVID-19. With an updated safe and effective COVID-19 booster shot now available, health experts are urging people to get both the flu and COVID vaccines in order to protect themselves this fall and winter.

Doctors recommend patients get both their flu and Covid booster by the end of this month for maximum protection against the two viruses.
Photo: CDC/Upslash

Since 2010, the Centers for Disease Control and Prevention (CDC) has recommended annual flu vaccines for everyone six months and older, with few exceptions. New this year is an added recommendation for a higher dose for those 65 and older. The CDC has also recommended the use of updated COVID-19 boosters from Pfizer-BioNTech for people ages 12 years and older and from Moderna for people ages 18 years and older.

If you have not yet received your COVID-19 booster shot, or if you still have yet to receive an initial dose, it’s not too late.

"I urge everybody who is eligible to get a COVID booster to do so, and the reasons why are multifactorial. Number one is because your immunity wanes and you need to protect yourself. Number two is that the virus has changed slightly and the newest booster is most effective at protecting against those changes, " says Dr. Bill Walsh, an OSF HealthCare chief medical officer.

Dr. Walsh adds that it is important to get the seasonal flu shot as well as a COVID shot because they protect against different viruses.

"Please understand that the recommendation is for both the flu shot and the COVID shot. There is no cross reactivity even though the symptoms might be similar between COVID-19 and influenza. The influenza shot will not help against COVID, and the COVID vaccination will not protect you against influenza, " Dr. Walsh explains.

The timing of when to get your flu shot and COVID booster can be confusing. The CDC says if you haven’t yet gotten your initial recommended dose of the COVID-19 vaccine, to get one as soon as you can. Health experts typically recommend getting your seasonal flu vaccine by the end of October for best protection during the peak of flu season, and say it is safe to get both vaccines during the same visit.

"There are many times when you get more than one vaccine. Most of the time when you get a tetanus shot, it also includes pertussis. Many of the vaccinations pediatricians give to children have more than one vaccine in each shot. So, it is standard and normal for more than one vaccine to occur at a time, " Dr. Walsh says.

Dr. Walsh adds getting both shots done at once alleviates having to make multiple trips to your doctor’s office or local pharmacy. But this route may not be for everyone.

As with all vaccinations, there are mild side effects that both vaccines can cause, such as joint or muscle pain, fatigue, and chills. If you have experienced side effects from vaccines in the past and it took a couple days for them to subside, you may opt to get the vaccines at separate times.

"You know yourself best. If you are certain that you will get them both despite not getting them at one appointment, then that is completely fine, too. You may want to space them out because sometimes you have side effects. There have been a lot of questions about whether to get them both in one arm or in different arms so you have different injection sites. That really boils down to personal preference, " advises Dr. Walsh.

The important thing is making sure you do get both of these vaccinations to protect both yourself and your loved ones. Because the holiday season is approaching, you may have holiday gatherings on your calendar over the next few months. If you get your flu shot in October but choose to wait to get your COVID-19 booster at a later date, Dr. Walsh recommends getting it at least two weeks before any large gatherings in order to ensure the best protection against the virus.

To schedule your seasonal flu vaccine and COVID-19 booster, make an appointment with your primary care provider or local pharmacy. Talk to your primary care provider if you have any questions about either vaccine.

Covid-19 booster shots available starting Monday, Sept 12

CHAMPAIGN -- Champaign County residents over the aged 65 and older will be able to receive the latest Moderna or Pfizer Coronavirus booster shoot starting Monday, September 12, at the Champaign-Urbana Public Health District office.

Due to the current limited supply of the vaccine, administration of the boosters shots will prioritize to the vulnerable members of the population, according to CUPHD. An appointment is required and can be made online at https://www.signupgenius.com/go/60B054CA8A82CA5F94-bivalent or by phone at (217) 531-4934.

The COVID-19 bivalent vaccination, which contains updated protection from the Omicron BA.4 and BA.5 variants, was approved by the Centers for Disease Control and Prevention on September 1. The updated COVID-19 booster from Pfizer-BioNTech is recommended people ages 12 years old and older and those 18 years and up for the Moderna version.

The booster shot will also be available at area hospitals. Availability and appointment information for OSF HealthCare will be posted here: https://www.osfhealthcare.org/covid19/vaccine/. Carle Health will also offer the booster shots and will announce availability in the near future here: https://carle.org/Home/COVID-19-Resources/COVID-19-Booster-Information. At this time, Christie Clinic recommends patients utilize community vaccine clinics or visit vaccines.gov for local availability of the vaccine.


The risk of heart infection higher after Covid when compared to incidence post-vaccination

Study finds the risk of myocarditis was substantially higher in the four weeks after COVID-19 infection than after a first dose of a COVID-19 vaccine.
DALLAS -- In a detailed analysis of nearly 43 million people, the risk of myocarditis in unvaccinated individuals after COVID-19 infection was at least 11 times higher compared to people who developed myocarditis after receiving a COVID-19 vaccine or booster dose, according to new research published today in the American Heart Association’s flagship, peer-reviewed journal Circulation. This analysis included data from England’s National Immunization database for people ages 13 and older who received at least one dose of a COVID-19 vaccine between December 1, 2020 and December 15, 2021 in England.

Several previous studies and reports from public health agencies around the world including the U.S. Centers for Disease Control and Prevention have highlighted a possible connection and potentially increased risk of myocarditis after receiving an mRNA COVID-19 vaccine, generating considerable scientific, policy and public interest.

Typically thought to be trigged by a viral infection, myocarditis is the inflammation of the heart muscle, the myocardium. This condition is uncommon and may temporarily or permanently weaken the heart muscle and the heart’s electrical system, which keeps the heart beating normally. An episode of myocarditis may resolve on its own or with treatment, and may result in lasting damage to the heart. In the general population not during a global pandemic, it is estimated that approximately 10 to 20 people per 100,000 are diagnosed with myocarditis each year, according to the American Heart Association’s 2021 scientific statement on myocarditis.

“We found that across this large dataset, the entire COVID-19-vaccinated population of England during an important 12-month period of the pandemic when the COVID-19 vaccines first became available, the risk of myocarditis following COVID-19 vaccination was quite small compared to the risk of myocarditis after COVID-19 infection,” says first author of the study Martina Patone, Ph.D., a statistician at the Nuffield Department of Primary Health Care Sciences at the University of Oxford in Oxford, England. “This analysis provides important information that may help guide public health vaccine campaigns, particularly since COVID-19 vaccination has expanded in many parts of the world to include children as young as 6 months old.”

In this study, Patone and colleagues evaluated England’s National Immunization database of COVID-19 vaccinations for all people ages 13 or older who had received at least one dose of the ChAdOx1 (a two-dose adenovirus-vector COVID-19 vaccine developed by the University of Oxford and AstraZeneca, most similar to the one-dose Johnson & Johnson/Janssen COVID-19 vaccine available in the U.S.), the Pfizer-BioNTech or the Moderna COVID-19 vaccine (the same mRNA vaccines available in the U.S.) between December 1, 2020 and December 15, 2021. This dataset totaled nearly 43 million people, which included more than 21 million who had received a booster dose of any of the COVID-19 vaccines (meaning they had received a total of 3 doses of a COVID-19 vaccine). The database detailed the type of COVID-19 vaccines received, dates received and dose sequencing, along with individual demographic information including age and sex for each individual. Nearly 6 million people tested positive for COVID-19 infection either before or after COVID-19 vaccination during the study period.

England’s National Immunization database records were then cross-referenced and matched to the national offices with data on COVID-19 infection, hospital admission and death certificates for the same time period, December 1, 2020 through December 15, 2021. Individuals were classified based on age and sex to reveal which groups had the highest risk of myocarditis after a COVID-19 vaccine or after COVID-19 infection and hospitalization. The authors used the self-controlled case series (SCCS) method, which was developed to estimate the relative incidence of an acute event in a pre-defined post-vaccination risk period (1-28 days), compared to other times (pre-vaccination or long after vaccination). Being a within-person comparison, the analyses were controlled to adjust for any fixed characteristics, including sex, race or ethnicity, or chronic health conditions.

In the overall dataset of nearly 43 million people, the analyses found:

  • Fewer than 3,000 (n=2,861), or 0.007%, people were hospitalized or died with myocarditis during the one-year study period. 617 of these cases of myocarditis occurred during days 1-28 after receiving a COVID-19 vaccination, of which 514 were hospitalized.
  • People who were infected with COVID-19 before receiving any doses of the COVID-19 vaccines were 11 times more at risk for developing myocarditis during days 1-28 after a COVID-19 positive test.
  • The risk of COVID-19 infection-related myocarditis risk was cut in half among people infected after vaccination (received at least one dose of a COVID-19 vaccine).
  • The risk of myocarditis increased after a first dose of the ChAdOx1 COVID-19 vaccine (an adenovirus-vector vaccine most similar to the Johnson & Johnson/Janssen COVID-19 vaccine available in the U.S.) and after a first, second and booster dose of any of the mRNA COVID-19 vaccines. However, the risk of vaccine-associated myocarditis was lower compared to the risk of COVID-19 infection-associated myocarditis, except for after a second dose of the Moderna vaccine.
  • Myocarditis risk was found to be higher during days 1-28 after a second dose of the Moderna COVID-19 vaccine for people of all genders and ages, and the risk also persisted after a booster dose of the Moderna vaccine. However, people receiving a booster dose of Moderna were, on average, younger in comparison to those who received a booster dose of the ChAdOx1 or Pfizer-BioNTech vaccine, therefore, results may not be generalizable to all adults.
  • Risk of COVID-19 vaccine-associated myocarditis among women:

  • Of the nearly 21 million women, 7.2 million (34%) were younger than age 40, and a slightly increased risk of myocarditis was found among this younger age group after receiving a second dose of the Moderna COVID-19 vaccine: 7 estimated extra cases of myocarditis for every one million women vaccinated.
  • Among women older than age 40, a slight increased risk of myocarditis was associated with receiving a first or third dose of the Pfizer-BioNTech COVID-19 vaccine, respectively 3 and 2 estimated additional cases of myocarditis for every one million women vaccinated.
  • Risk of COVID-19 infection-associated myocarditis among women:

  • Among women younger than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 8 extra cases associated with having COVID-19 infection before vaccination.
  • Among women older than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 51 extra cases associated with having COVID-19 infection before vaccination.
  • Risk of COVID-19 vaccine-associated myocarditis among men:

  • Among the 18 million men in the dataset, all of whom received at least one COVID-19 vaccine, more than 6 million men (34%) were younger than age 40.
  • An increased risk of vaccine-associated myocarditis was found in men ages 40 and younger after a first dose of either of the mRNA COVID-19 vaccines (4 and 14 estimated extra cases for every one million men vaccinated with respectively Pfizer or Moderna vaccine), or a second dose of any of the three COVID-19 vaccines available in England during the study period: 14, 11 and 97 estimated additional cases of myocarditis for every one million men vaccinated, respectively for the ChAdOx1, the Pfizer-BioNTech or the Moderna vaccine.
  • The increased risk of developing myocarditis among males younger than age 40 was also higher after receiving two doses of the Moderna vaccine when compared to the risk of myocarditis after COVID-19 infection. The researchers noted, however, the average age of people who received the Moderna vaccine was 32 years, compared to the majority of those who received the other vaccines were older than age 40.
  • In men ages 40 and older, a slightly increased risk of myocarditis was found after a booster dose of either of the two mRNA vaccines (Pfizer-BioNTech or Moderna): 3 estimated extra cases of myocarditis for every one million men vaccinated with either mRNA vaccine.
  • Risk of COVID-19 infection-associated myocarditis among men:

  • Among men younger than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 16 extra cases associated with having infection before vaccination, with the only exception of a second dose of Moderna vaccine.
  • Among men older than age 40, the risk of infection-associated myocarditis was higher compared to the risk of vaccine-associated myocarditis: 85 extra cases associated with having infection before vaccination.
  • “It is important for the public to understand that myocarditis is rare, and the risk of developing myocarditis after a COVID-19 vaccine is also rare. This risk should be balanced against the benefits of the COVID-19 vaccines in preventing severe COVID-19 infection. It is also crucial to understand who is at a higher risk for myocarditis and which vaccine type is associated with increased myocarditis risk, ” said Professor Nicholas Mills, Ph.D., the Butler British Heart Foundation Chair of Cardiology at the University of Edinburgh and a co-author of the paper. “These findings are valuable to help inform recommendations on the type of COVID-19 vaccines available for younger people and may also help shape public health policy and strategy for COVID-19 vaccine boosters. The SARS-CoV-2 virus continues to shift, and more contagious variants arise; our hope is that this data may enable a more well-informed discussion on the risk of vaccine-associated myocarditis when considered in contrast to the net benefits of COVID-19 vaccination,” said another co-author Julia Hippisley-Cox, F.R.C.P., professor of clinical epidemiology and general practice at the University of Oxford.

    Authors noted there are two unanswered questions that likely require further investigation. The first is about myocarditis risk among children ages 13-17 because there were too few cases of myocarditis to quantify the risk specific to this age group. Secondly, researchers were not able to directly compare the death rate after COVID-19 infection vs. death after COVID-19 vaccination since the database only included people who had received at least one COVID-19 vaccine. More expansive data and a different analysis are still needed to address these questions and numerous other COVID-19 topics.

    The study has two notable limitations. The number of cases of myocarditis among individuals who received a booster dose of the ChAdOx1 or Moderna vaccines was too small to calculate the risk of myocarditis. Additionally, researchers cannot exclude the possibility of over- or under-estimated risk due to misclassification of any health information in the database, though the U.K.’s National Health Service is known to provide timely and accurate data.

    COVID-19 second boosters now available for age-eligible county residents

    CHAMPAIGN -- Champaign County residents 65 and older can now receive a second Covid-19 booster. Citizens 50 and older with an underlying medical condition are also eligible to receive a second booster.

    This week, the Centers for Disease Control and Prevention (CDC) recommended on Tuesday, March 29, that "expanded eligibility for an additional booster dose for certain individuals who may be at higher risk of severe outcomes from COVID-19. Boosters are safe, and people over the age of 50 can now get an additional booster four months after their prior dose to increase their protection further."

    Eligible members of the community may sign-up online at https://www.signupgenius.com/go/60B054CA8A82CA5F94-2ndcovid to receive the vaccination at the Champaign-Urbana Public Health District office located at 201 W. Kenyon Road in Champaign.

    Vaccination appointments are being booked now for April 4 – 22 from 8:30 am – 4:00 pm.

    Boosters will also be available from Promise Healthcare, Carle Health, OSF Healthcare, and Christie Clinic. Patients are urged to contact their primary care provider for more information or to schedule an appointment.

    Meanwhile, those under the age of 50 and interested in receiving a second booster will have to wait for government approval for the time being. In a release issued today by the CUPHD, the "CDC, in collaboration with FDA and our public health partners, will continue to evaluate the need for additional booster doses for all Americans."

    Christie Clinic will offer the booster at most of their primary care offices. According to today's press release, appointments will be limited to Christie patients 50 years old and older. "If patients have an upcoming appointment, they are encouraged to discuss their eligibility with their primary care provider."

    Appointments for the second Covid-19 booster at Promise Healthcare can be made by calling (217) 356-1558.

    For more information visit vaccine.gov to find a vaccine site nearest to you or log into www.vaccinefinder.org for available appointments at local pharmacies.


    Young people recover quickly from rare effect caused by COVID-19 vaccine

    by American Heart Association
    Researchers say future studies should follow patients who have suffered vaccine-associated myocarditis over a longer term, since this study examined only the immediate course of patients and lacks follow-up data.
    Most young people under the age of 21 who developed suspected COVID-19 vaccine-related heart muscle inflammation known as myocarditis had mild symptoms that improved quickly, according to new research published today in the American Heart Association’s flagship journal Circulation.

    Myocarditis is a rare but serious condition that causes inflammation of the heart muscle. It can weaken the heart and affect the heart’s electrical system, which keeps the heart pumping regularly. It is most often the result of an infection and/or inflammation caused by a virus.

    "In June of this year, the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices reported a likely link between mRNA COVID-19 vaccination and myocarditis, particularly in people younger than 39. However, research continues to find COVID-19 vaccine-related cases of myocarditis uncommon and mostly mild," said Donald. M. Lloyd-Jones, M.D., Sc.M., FAHA, president of the American Heart Association, who was not involved in the study. "Overwhelmingly, data continue to indicate that the benefits of COVID-19 vaccination – 91% effective at preventing complications of severe COVID-19 infection including hospitalization and death – far exceed the very rare risks of adverse events, including myocarditis."

    "The highest rates of myocarditis following COVID-19 vaccination have been reported among adolescent and young adult males. Past research shows this rare side effect to be associated with some other vaccines, most notably the smallpox vaccine," said the new study’s senior author Jane W. Newburger, M.D., M.P.H., FAHA, associate chair of Academic Affairs in the Department of Cardiology at Boston Children’s Hospital, the Commonwealth Professor of Pediatrics at Harvard Medical School and a member of the American Heart Association’s Council on Lifelong Congenital Heart Disease and Heart Health in the Young. "While current data on symptoms, case severity and short-term outcomes is limited, we set out to examine a large group of suspected cases of this heart condition as it relates to the COVID-19 vaccine in teens and adults younger than 21 in North America."

    Using data from 26 pediatric medical centers across the United States and Canada, researchers reviewed the medical records of patients younger than 21 who showed symptoms, lab results or imaging findings indicating myocarditis within one month of receiving a COVID-19 vaccination, prior to July 4, 2021. Cases of suspected vaccine-associated myocarditis were categorized as "probable" or "confirmed" using CDC definitions.

    Of the 139 teens and young adults, ranging from 12 to 20 years of age, researchers identified and evaluated:

  • Most patients were white (66.2%), nine out of 10 (90.6%) were male and median age was 15.8 years.
  • Nearly every case (97.8%) followed an mRNA vaccine, and 91.4% occurred after the second vaccine dose.
  • Onset of symptoms occurred at a median of 2 days following vaccine administration.
  • Chest pain was the most common symptom (99,3%); fever and shortness of breath each occurred in 30.9% and 27.3% of patients, respectively.
  • About one in five patients (18.7%) was admitted to intensive care, but there were no deaths. Most patients were hospitalized for two or three days.
  • More than three-fourths (77.3%) of patients who received a cardiac MRI showed evidence of inflammation of or injury to the heart muscle.
  • Nearly 18.7% had at least mildly decreased left ventricular function (squeeze of the heart) at presentation, but heart function had returned to normal in all who returned for follow-up.
  • "These data suggest that most cases of suspected COVID-19 vaccine-related myocarditis in people younger than 21 are mild and resolve quickly," said the study’s first author, Dongngan T. Truong, M.D., an associate professor of pediatrics in the division of cardiology at the University of Utah and a pediatric cardiologist at Intermountain Primary Children’s Hospital in Salt Lake City. "We were very happy to see that type of recovery. However, we are awaiting further studies to better understand the long-term outcomes of patients who have had COVID-19 vaccination-related myocarditis. We also need to study the risk factors and mechanisms for this rare complication."

    Researchers say future studies should follow patients who have suffered vaccine-associated myocarditis over a longer term, since this study examined only the immediate course of patients and lacks follow-up data. Additionally, there are several important limitations to consider. The study design did not allow scientists to estimate the percentage of those who received the vaccine and who developed this rare complication, nor did it allow for a risk/benefit ratio examination. The patients included in this study were also evaluated at academic medical centers and may have been more seriously ill than other cases found in a community.

    "It is important for health care professionals and the public to have information about early signs, symptoms and the time course of recovery of myocarditis, particularly as these vaccines become more widely available to children," Truong said. "Studies to determine long-term outcomes in those who have had myocarditis after COVID-19 vaccination are also planned."

    Researchers recommend that health care professionals consider myocarditis in individuals presenting with chest pain after receiving a COVID-19 vaccine, especially in boys and young men in the first week after the second vaccination.

    "This study supports what we have been seeing – people identified and treated early and appropriately for COVID-19 vaccine-related myocarditis typically experience mild cases and short recovery times," Lloyd-Jones said. "These findings also support the American Heart Association’s position that COVID-19 vaccines are safe, highly effective and fundamental to saving lives, protecting our families and communities against COVID-19, and ending the pandemic. Please get your child vaccinated as soon as possible."

    AHA agrees with CDC guidelines, recommends Covid-19 booster

    (Amreican Heart Association) -- As the Omicron variant spreads, COVID-19 vaccination is more important than ever. The American Heart Association continues to align with expert guidance from the U.S. Centers for Disease Control and Prevention (CDC) – the nation’s infectious disease experts - regarding COVID-19 vaccinations and booster shots.

    Recently, the CDC extended recommendations for a booster dose of COVID-19 vaccines to all adults ages 18 and older, including the allowance to "mix & match" the types of COVID-19 vaccines for the booster dose. According to the CDC, the additional COVID-19 vaccine dose may be from any of the three COVID-19 vaccines authorized or approved in the U.S. – either the Pfizer-BioNTech, Moderna or Johnson & Johnson COVID-19 vaccines. The mix & match regimen is available only for booster doses of the COVID-19 vaccines, not for the primary vaccination series, which still requires the same, initial two doses of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.

    The CDC recommends a booster of either the Moderna or Pfizer-BioNTech COVID-19 vaccine (mRNA vaccines) for all adults at least 6 months after receiving two-doses of the same mRNA COVID-19 vaccine. Adults ages 18 and older who previously received one dose of the Johnson & Johnson COVID-19 vaccine (an adenovirus vector vaccine) are eligible for a booster dose two months after the initial dose. They may select a second dose of the Johnson & Johnson COVID-19 vaccine or a booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccines.

    The American Heart Association/American Stroke Association, a global force for longer, healthier lives for all, affirms the CDC’s guidance on COVID-19 vaccines.

    The Association remains concerned about the continuing gaps in COVID-19 vaccination among people from all eligible age groups in the U.S. including people from diverse racial and ethnic groups and among pregnant women, especially in light of the Omicron variant. Therefore, it continues to urge all adults and children ages 5 and older in the U.S. to receive all COVID-19 vaccines as soon as they are eligible, as recommended by the CDC and fully approved or authorized for emergency use by the FDA.

    "With the Omicron variant spreading, we urge everyone 5 and older to get vaccinated against COVID-19 and get the booster when they are eligible. The booster shots are particularly important for adults ages 50 and older who have underlying medical conditions or any adult living in a long-term care facility," said American Heart Association volunteer President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA, who is also the Eileen M. Foell Professor of Heart Research, professor of preventive medicine, medicine and pediatrics, and chair of the department of preventive medicine at Northwestern University’s Feinberg School of Medicine in Chicago.

    "As cited by the CDC, recently published research indicates a COVID-19 vaccine booster dose provides increased protection against COVID-19 infection, severe complications and death. Breakthrough cases of COVID-19 infection after vaccination are possible, however, serious side effects and needing hospitalization among people who are vaccinated continue to be rare and mild. The benefits of the vaccine and boosters far outweigh the very limited risk."

    The Association also supports the CDC’s ongoing safety recommendations: mask wearing for all people regardless of vaccination status when indoors, frequent handwashing and social distancing. Along with COVID-19 vaccination, these safety protocols are essential to minimizing the spread of the COVID-19 virus and reducing the risk of infection, hospitalization and death.

    "As the COVID-19 pandemic impacts our families and communities for a second winter and holiday season, we encourage everyone to remain vigilant against the COVID-19 virus. The COVID-19 vaccines are paramount to saving lives, protecting our families and loved ones against COVID-19 infection, severe illness and death. We urge everyone to get vaccinated as soon as possible so that it is a winter filled with joyous memories," urged Lloyd-Jones.

    She had a change of heart on the Covid vaccine

    (NAPSI) — Stephanie Bramlett of Winder, Georgia, is one of many in the Southeast region who has experienced the effects of COVID-19 firsthand. Earlier this year, when the entrepreneur and mother of three was told she could get vaccinated, she was hesitant. She eats well, exercises regularly and never gets sick with the flu, so she assumed she’d be fine even if she was exposed to the virus. "I didn’t want to be first," Bramlett said. "It felt too new." 

    Then her son attended church camp, and, unknowingly, brought the virus home. Bramlett woke up one morning with a throbbing headache, 103-degree fever and fatigue. She also discovered she had lost her sense of smell and taste, telltale symptoms of the coronavirus. Eleven days later, she couldn’t get out of bed. Her head was hurting so badly that her husband took her to the hospital where they checked her for a brain bleed. 

    "I was terrified because I had never had head pain like this before," said Bramlett. She was diagnosed with inflammation of her brain vessels and myocarditis, a heart condition that made her heart feel like she was constantly running on a treadmill. Her body swelled as her kidney functions failed. Her recovery ultimately took 72 days. 

    "It was really, really scary and I don’t wish that on anybody," Bramlett says of the experience.

    While Bramlett was ill, she asked her doctor if she could get vaccinated, but her medical team advised that she had to wait until she was feeling better. The moment she was cleared, Bramlett went right to the drug store for her vaccine.

    "The hardest part was that people were dying all around me the entire time I was sick—healthy people, young people," Bramlett reflects. “I just felt so stupid. Here’s this vaccine available and I just assumed that it wouldn’t happen to me."

    In fact, COVID-19 remains a serious threat across the U.S. as we head into the pandemic’s second winter. The Delta variant, which now makes up virtually all cases in the country, spreads more easily than the common cold and has led to a dramatic increase in hospitalizations nationwide. This rise in serious cases and deaths was most pronounced in the Southern U.S., where vaccination rates are lower.

    What The CDC Says

    According to the Centers For Disease Control and Prevention, people who have not yet been vaccinated are 29 times more likely to be hospitalized and 11 times more likely to die from COVID-19 complications, compared to those who have already received their vaccine.

    Other CDC data reveals people ages 18 to 49 are the largest demographic hospitalized for COVID-19 as of September 25. Studies also show that even for individuals who have a mild case of COVID-19 and avoid hospitalization, they remain at risk of post-COVID symptoms, often called long COVID, that may last for weeks, months or longer. Symptoms of long COVID appear to affect as many as one in three people infected with the virus.

    Bramlett now shares her experience with her friends and family to encourage them to consider being vaccinated. She urges everyone to talk to their doctor and learn about how they can keep themselves healthy and safe, so they can be present for their own children and families. To those still hesitant, Stephanie Bramlett says: "I understand. I understand that people are scared. I respect whatever decision you make or how you feel about the COVID-19 vaccine, but I would encourage people to do what they have to do to find the truth and do what you need to do to keep yourself healthy and safe."

    Learn More

    COVID-19 vaccines are safe, effective, widely available and free to everyone in the U.S. age twelve and older. Additionally, the FDA has formally approved Pfizer’s COVID-19 vaccine in the U.S. for those sixteen and older. 

    If you have questions about the COVID-19 vaccines, talk to a doctor or pharmacist, and visit www.GetVaccineAnswers.org for the latest information.

    Pfizer COVID-19 booster available starting next week

    Today, the Champaign-Urbana Public Health District (CUPHD) announced that Covid-19 Pfizer booster shots will be available beginning next week.

    Eligible individuals who want to upgrade their body's ability to fight off Coronavirus infection can receive a booster vaccination at a community clinic or participating pharmacy.

    The Pfizer booster will be available to residents 65 years of age or older, folks between the ages 50 and 64 with underlying health conditions, healthcare workers, and first responders who have completed their 1st and 2nd doses of the Pfizer vaccine. Individuals must also have received their second Pfizer dose six or months ago.

    According to a release issued today, "... the Centers for Disease Control and Prevention (CDC), many of the people who are now eligible to receive a booster shot received their initial vaccine early in the vaccination program and will benefit from additional protection. With the Delta variant’s dominance as the circulating strain and cases of COVID-19 increasing significantly across the United States, a booster shot will help strengthen protection against severe disease in those populations who are at high risk for exposure to COVID-19 or the complications from severe disease. Additional information can be found at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html."

    Community clinics will be held at the iHotel and Conference Center, located at 1900 S. 1st Street in Champaign October 5-7 from 9a until 4pm. No appointment is needed.

    Booster shots will also be available at the Kohl’s Plaza at 1901 N. Market Street in Champaign. The Pfizer booster will be available to all eligible individuals at this location. Booster appointments can be scheduled through MyCarle and at carle.org/covid-19 for October 5th – 7th, 12th – 14th and 19th – 21st from 10:00a – 5:30p.

    Appointments are also available at local pharmacies. Visit www.vaccinefinder.org for locations, times and availability.

    As Covid cases surge across the country, CDC only tracks a fraction of breakthrough cases


    Jenny Deam and Jodi S. Cohen, ProPublica


    Meggan Ingram was fully vaccinated when she tested positive for COVID-19 early this month. The 37-year-old’s fever had spiked to 103 and her breath was coming in ragged bursts when an ambulance rushed her to an emergency room in Pasco, Washington, on Aug. 10. For three hours she was given oxygen and intravenous steroids, but she was ultimately sent home without being admitted.

    Seven people in her house have now tested positive. Five were fully vaccinated and two of the children are too young to get a vaccine.

    As the pandemic enters a critical new phase, public health authorities continue to lack data on crucial questions, just as they did when COVID-19 first tore through the United States in the spring of 2020. Today there remains no full understanding on how the aggressively contagious delta variant spreads among the nearly 200 million partially or fully vaccinated Americans like Ingram, or on how many are getting sick.

    The nation is flying blind yet again, critics say, because on May 1 of this year — as the new variant found a foothold in the U.S. — the Centers for Disease Control and Prevention mostly stopped tracking COVID-19 in vaccinated people, also known as breakthrough cases, unless the illness was severe enough to cause hospitalization or death.

    Individual states now set their own criteria for collecting data on breakthrough cases, resulting in a muddled grasp of COVID-19’s impact, leaving experts in the dark as to the true number of infections among the vaccinated, whether or not vaccinated people can develop long-haul illness, and the risks to unvaccinated children as they return to school.



    If you’re limiting yourself to a small subpopulation with only hospitalizations and deaths, you risk a biased viewpoint.


    "It’s like saying we don’t count,” said Ingram after learning of the CDC’s policy change. COVID-19 roared through her household, yet it is unlikely any of those cases will show up in federal data because no one died or was admitted to a hospital.

    The CDC told ProPublica in an email that it continues to study breakthrough cases, just in a different way. "This shift will help maximize the quality of the data collected on cases of greatest clinical and public health importance,” the email said.

    In addition to the hospitalization and death information, the CDC is working with Emerging Infections Program sites in 10 states to study breakthrough cases, including some mild and asymptomatic ones, the agency’s email said.

    Under pressure from some health experts, the CDC announced Wednesday that it will create a new outbreak analysis and forecast center, tapping experts in the private sector and public health to guide it to better predict how diseases spread and to act quickly during an outbreak.

    Tracking only some data and not releasing it sooner or more fully, critics say, leaves a gaping hole in the nation’s understanding of the disease at a time when it most needs information.

    "They are missing a large portion of the infected," said Dr. Randall Olsen, medical director of molecular diagnostics at Houston Methodist Hospital in Texas. "If you’re limiting yourself to a small subpopulation with only hospitalizations and deaths, you risk a biased viewpoint."

    On Wednesday, the CDC released a trio of reports that found that while the vaccine remained effective at keeping vaccinated people out of the hospital, the overall protection appears to be waning over time, especially against the delta variant.

    Among nursing home residents, one of the studies showed vaccine effectiveness dropped from 74.7% in the spring to just 53.1% by midsummer. Similarly, another report found that the overall effectiveness among vaccinated New York adults dropped from 91.7% to just under 80% between May and July.

    The new findings prompted the Biden administration to announce on Wednesday that people who got a Moderna or Pfizer vaccine will be offered a booster shot eight months after their second dose. The program is scheduled to begin the week of Sept. 20 but needs approval from the Food and Drug Administration and a CDC advisory committee.



    No vaccine is 100% percent effective against transmission, health officials warned.


    This latest development is seen by some as another example of shifting public health messaging and backpedaling that has accompanied every phase of the pandemic for 19 months through two administrations. A little more than a month ago, the CDC and the FDA released a joint statement saying that those who have been fully vaccinated "do not need a booster shot at this time.”

    The vaccine rollout late last year came with cautious optimism. No vaccine is 100% percent effective against transmission, health officials warned, but the three authorized vaccines proved exceedingly effective against the original COVID-19 strain. The CDC reported a breakthrough infection rate of 0.01% for the months between January and the end of April, although it acknowledged it could be an undercount.

    As summer neared, the White House signaled it was time for the vaccinated to celebrate and resume their pre-pandemic lives.

    Trouble, though, was looming. Outbreaks of a new, highly contagious variant swept India in the spring and soon began to appear in other nations. It was only a matter of time before it struck here, too.

    "The world changed," said Dr. Eric Topol, director of the Scripps Research Translational Institute, "when delta invaded."

    The current crush of U.S. cases — well over 100,000 per day — has hit the unvaccinated by far the hardest, leaving them at greater risk of serious illness or death. The delta variant is considered at least two or three times more infectious than the original strain of the coronavirus. For months much of the focus by health officials and the White House has been on convincing the resistant to get vaccinated, an effort that has so far produced mixed results.

    Yet as spring turned to summer, scattered reports surfaced of clusters of vaccinated people testing positive for the coronavirus. In May, eight vaccinated members of the New York Yankees tested positive. In June, 11 employees of a Las Vegas hospital became infected, eight of whom were fully vaccinated. And then 469 people who visited the Provincetown, Massachusetts, area between July 3 and July 17 became infected even though 74% of them were fully vaccinated, according to the CDC’s Morbidity and Mortality Weekly Report.

    While the vast majority of those cases were relatively mild, the Massachusetts outbreak contributed to the CDC reversing itself on July 27 and recommending that even vaccinated people wear masks indoors — 11 weeks after it had told them they could jettison the protection.

    And as the new CDC data showed, vaccines continue to effectively shield vaccinated people against the worst outcomes. But those who get the virus are, in fact, often miserably sick and may chafe at the notion that their cases are not being fully counted.

    "The vaccinated are not as protected as they think," said Topol, "They are still in jeopardy."

    The CDC tracked all breakthrough cases until the end of April, then abruptly stopped without making a formal announcement. A reference to the policy switch appeared on the agency’s website in May about halfway down the homepage.

    "I was shocked," said Dr. Leana Wen, a physician and visiting professor of health policy and management at George Washington University. "I have yet to hear a coherent explanation of why they stopped tracking this information.”

    The CDC said in an emailed statement to ProPublica that it decided to focus on the most serious cases because officials believed more targeted data collection would better inform "response research, decisions, and policy."

    Sen. Edward MMarkey, D-Mass., became alarmed after the Provincetown outbreak and wrote to CDC director Dr. Rochelle Walensky on July 22, questioning the decision to limit investigation of breakthrough cases. He asked what type of data was being compiled and how it would be shared publicly.

    It is unclear how often breakthroughs occur or how widely cases are spreading among the vaccinated.

    "The American public must be informed of the continued risk posed by COVID-19 and variants, and public health and medical officials, as well as health care providers, must have robust data and information to guide their decisions on public health measures," the letter said.

    Markey asked the agency to respond by Aug. 12. So far the senator has received no reply, and the CDC did not answer ProPublica’s question about it.

    When the CDC halted its tracking of all but the most severe cases, local and state health departments were left to make up their own rules.

    There is now little consistency from state to state or even county to county on what information is gathered about breakthrough cases, how often it is publicly shared, or if it is shared at all.

    "We’ve had a patchwork of information between states since the beginning of the pandemic,” said Jen Kates, senior vice president and director of global health and HIV policy at Kaiser Family Foundation.

    She is co-author of a July 30 study that found breakthrough cases across the U.S. remained rare, especially those leading to hospitalization or death. However, the study acknowledged that information was limited because state reporting was spotty. Only half the states provide some data on COVID-19 illnesses in vaccinated people.

    "There is no single, public repository for data by state or data on breakthrough infections, since the CDC stopped monitoring them,” the report said.

    In Texas, where COVID-19 cases are skyrocketing, a state Health and Human Services Commission spokesperson told ProPublica in an email the state agency was "collecting COVID-19 vaccine breakthrough cases of heightened public health interest that result in hospitalization or fatality only."

    Other breakthrough case information is not tracked by the state, so it is unclear how often breakthroughs occur or how widely cases are spreading among the vaccinated. And while Texas reports breakthrough deaths and hospitalizations to the CDC, the information is not included on the state’s public dashboard.

    "We will be making some additions to what we are posting, and these data could be included in the future," the spokesperson said.

    I thought, ‘COVID is over and I’m going to Disney World,’

    South Carolina, on the other hand, makes public its breakthrough numbers on hospitalizations and deaths. Milder breakthrough cases may be included in the state’s overall COVID-19 numbers but they are not labeled as such, said Jane Kelly, an epidemiologist at the South Carolina Department of Health and Environmental Control.

    "We agree with the CDC,” she said, "there’s no need to spend public health resources investigating every asymptomatic or mild infection.”

    In Utah, state health officials take a different view. "From the beginning of the pandemic we have been committed to being transparent with our data reporting and … the decision to include breakthrough case data on our website is consistent with that approach," said Tom Hudachko, director of communications for the Utah Department of Health.

    Some county-level officials said they track as many breakthrough cases as possible even if their state and the CDC does not.

    For instance, in Clark County, Nevada, home of Las Vegas, the public health website reported that as of last week there were 225 hospitalized breakthrough cases but 4,377 vaccinated people overall who have tested positive for the coronavirus.

    That means that less than 5% of reported breakthrough cases resulted in hospitalization. "The Southern Nevada Health District tracks the total number of fully vaccinated individuals who test positive for COVID-19 and it is a method to provide a fuller picture of what is occurring in our community,” said Stephanie Bethel, a spokesperson for the health district in an email.

    Sara Schmidt, a 44-year-old elementary school teacher in Alton, Illinois, is another person who has likely fallen through the data hole.

    "I thought, ‘COVID is over and I’m going to Disney World,’" she said. She planned a five-day trip for the end of July with her parents. Not only had she been fully vaccinated, receiving her second shot in March, she is also sure she had COVID-19 in the summer of 2020. Back then she had all the symptoms but had a hard time getting tested. When she finally did, the result came back negative, but her doctor told her to assume it was inaccurate.

    "My guard was down," she said. She was less vigilant about wearing a mask in the Florida summer heat, assuming she was protected by the vaccination and her presumed earlier infection.

    On the July 29 plane trip home, she felt mildly sick. Within days she was "absolutely miserable." Her coughing continued to worsen, and each time she coughed her head pounded. On Aug. 1 she tested positive. Her parents were negative.

    Now, three weeks later, she is far from fully recovered and classes are about to begin at her school. There’s a school mask mandate, but her students are too young to be vaccinated. "I’m worried I will give it to them, or I will get it for a third time," she said.

    But it is doubtful her case will be tracked because she was never hospitalized. That infuriates her, she said, because it downplays what is happening.

    "Everyone has a right to know how many breakthrough cases there are," she said, "I was under the impression that if I did get a breakthrough case, it would just be sniffles. They make it sound like everything is under control and it’s not."

    This story was originally published by ProPublica on August 20, 2021. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

    Serious Covid cases on the rise in young adults

    The CDC recommends that people wear masks in public at events and gatherings when they are around other people in settings they can not observe social distancing.
    Photo: Matt Moloney/StockSnap

    By Will Stone
    After spending much of the past year tending to elderly patients, doctors are seeing a clear demographic shift: young and middle-aged adults make up a growing share of the patients in covid-19 hospital wards.

    It's both a sign of the country's success in protecting the elderly through vaccination and an urgent reminder that younger generations will pay a heavy price if the outbreak is allowed to simmer in communities across the country.


    The explosion of cases in Michigan underscores the potential fallout of loosening restrictions.

    "We're now seeing people in their 30s, 40s and 50s — young people who are really sick," said Dr. Vishnu Chundi, a specialist in infectious diseases and chair of the Chicago Medical Society's covid-19 task force. "Most of them make it, but some do not. … I just lost a 32-year-old with two children, so it's heartbreaking."

    Nationally, adults under 50 now account for the most hospitalized covid patients in the country — about 36% of all hospital admissions. Those ages 50 to 64 account for the second-highest number of hospitalizations, or about 31%. Meanwhile, hospitalizations among adults 65 and older have fallen significantly.

    About 32% of the U.S. population is now fully vaccinated, but the vast majority are people older than 65 — a group that was prioritized in the initial phase of the vaccine rollout.

    Although new infections are gradually declining nationwide, some regions have contended with a resurgence of the coronavirus in recent months — what some have called a "fourth wave" — propelled by the B.1.1.7 variant, first identified in the United Kingdom, which is estimated to be somewhere between 40% and 70% more contagious.

    As many states ditch pandemic precautions, this more virulent strain still has ample room to spread among the younger population, which remains broadly susceptible to the disease.

    The emergence of more dangerous strains of the virus in the U.S. — including variants first discovered in South Africa and Brazil — has made the vaccination effort all the more urgent.

    "We are in a whole different ballgame," said Judith Malmgren, an epidemiologist at the University of Washington.

    Rising infections among young adults create a "reservoir of disease" that eventually "spills over into the rest of society" — one that has yet to reach herd immunity — and portends a broader surge in cases, she said.

    Fortunately, the chance of dying of covid remains very small for people under 50, but this age group can become seriously ill or experience long-term symptoms after the initial infection. People with underlying conditions such as obesity and heart disease are also more likely to become seriously ill.

    "B.1.1.7 doesn't discriminate by age, and when it comes to young people, our messaging on this is still too soft," Malmgren said.


    Hospitals Filled With Younger, Sicker People

    Across the country, the influx of younger patients with covid has startled clinicians who describe hospital beds filled with patients, many of whom appear sicker than what was seen during previous waves of the pandemic.

    "A lot of them are requiring ICU care," said Dr. Michelle Barron, head of infection prevention and control at UCHealth, one of Colorado's large hospital systems, as compared with earlier in the pandemic.

    The median age of covid patients at UCHealth hospitals has dropped by more than 10 years in the past few weeks, from 59 down to about 48 years old, Barron said.

    "I think we will continue to see that, especially if there's not a lot of vaccine uptake in these groups," she said.

    While most hospitals are far from the onslaught of illness seen during the winter, the explosion of cases in Michigan underscores the potential fallout of loosening restrictions when a large share of adults are not yet vaccinated.

    There's strong evidence that all three vaccines being used in the U.S. provide good protection against the U.K. variant.

    One study suggests that the B.1.1.7 variant doesn't lead to more severe illness, as was previously thought. However, patients infected with the variant appear more likely to have more of the virus in their bodies than those with the previously dominant strain, which may help explain why it spreads more easily.

    "We think that this may be causing more of these hospitalizations in younger people," said Dr. Rachael Lee at the University of Alabama-Birmingham hospital.


    "We don't yet have enough younger adults vaccinated to counteract the increased ease with which the variants spread."

    Lee's hospital also has observed an uptick in younger patients. As in other Southern states, Alabama has a low rate of vaccine uptake.

    But even in Washington state, where much of the population is opting to get the vaccine, hospitalizations have been rising steadily since early March, especially among young people. In the Seattle area, more people in their 20s are now being hospitalized for covid than people in their 70s, according to Dr. Jeff Duchin, public health chief officer for Seattle and King County.

    "We don't yet have enough younger adults vaccinated to counteract the increased ease with which the variants spread," said Duchin at a recent press briefing.

    Nationwide, about 32% of people in their 40s are fully vaccinated, compared with 27% of people in their 30s. That share drops to about 18% for 18- to 29-year-olds.

    "I'm hopeful that the death curve is not going to rise as fast, but it is putting a strain on the health system," said Dr. Nathaniel Schlicher, an emergency physician and president of the Washington State Medical Association.

    Schlicher, also in his late 30s, recalls with horror two of his recent patients — close to his age and previously healthy — who were admitted with new-onset heart failure caused by covid.

    "I've seen that up close and that's what scares the hell out of me," he said.

    "I understand young people feeling invincible, but what I would just tell them is — don't be afraid of dying, be afraid of heart failure, lung damage and not being able to do the things that you love to do."


    Will Younger Adults Get Vaccinated?

    Doctors and public health experts hope that the troubling spike in hospitalizations among the younger demographic will be temporary — one that vaccines will soon counteract. It was only on April 19 that all adults became eligible for a covid vaccine, although they were available in some states much sooner.

    But some concerning national polls indicate a sizable portion of teens and adults in their 20s and 30s don't necessarily have plans to get vaccinated.

    "We just need to make it super easy — not inconvenient in any way," said Malmgren, the Washington epidemiologist. "We have to put our minds to it and think a little differently."

    Subscribe to KHN's free Morning Briefing.

    Backed by plenty of public and private cash, Rapid Covid Tests will be in stores soon

    by Hannah Norman

    Scientists and lawmakers agree that over-the-counter covid tests could allow desk workers to settle back into their cubicles and make it easier to reopen schools and travel.

    But even as entrepreneurs race their products to market, armed with millions of dollars in venture capital and government investment, the demand for covid testing has waned. Manufacturing and bureaucratic delays have also kept rapid tests from hitting store shelves in large numbers, though the industry was energized by the Food and Drug Administration’s greenlighting of two more over-the-counter tests Wednesday.

    Corporate giants and startups alike plan to offer a dizzying array of test options, most costing between $10 and $110. Their screening accuracy varies, as does the way consumers get results: collection kits mailed back to a lab, devices synced with artificial intelligence-enabled apps on a smartphone that spit out results within 15 minutes, and credit card-sized tests with strips of paper that must be dipped into a chemical substance.

    "At-home tests are one of the key steps to getting back to normal life," said Andy Slavitt, a member of the White House COVID-19 Response Team, during a February briefing.

    The Biden administration announced in March it will allocate $10 billion from the recently passed stimulus package for covid testing to expedite school reopenings, and earlier said it would invoke the Defense Production Act to manufacture more at-home tests. Separately, the federal government has already sent millions of Abbott Laboratories’ BinaxNOW rapid tests to states, and California, for instance, is giving 3 million of them to its most disadvantaged school districts for free.

    Large employers, like Google, sports leagues and the federal government, have already shelled out millions to regularly test their workers. Amazon just received emergency use authorization from the FDA for its own covid test and home collection kit, which it intends to use for its employee screening program.



    In February, the Biden administration cut a $232 million deal with Ellume, whose rapid antigen test was authorized by the FDA in December. Paired with an app, the test takes 15 minutes to analyze after a nose swab.


    Individuals who want to buy over-the-counter tests can bill their health insurance plans, which are required by the federal government in most cases to fully cover covid tests that have been authorized by the FDA.

    Everlywell, based in Austin, Texas, is an at-home diagnostic company that already sells its collection kit to consumers through its website and Walgreens, and will soon offer same-day delivery via DoorDash in a dozen cities. Dr. Marisa Cruz, Everlywell’s executive vice president of regulatory and clinical affairs, said buyers can seek reimbursement from their insurance plans for the kit’s $109 cost. The tests are also eligible for purchase with pretax dollars from health savings or flexible spending accounts, she said.

    Even with vaccines, epidemiologists say, rapid tests are desperately needed because more testing, along with mask-wearing and physical distancing, will get people back in offices and classrooms and help catch cases that go undetected. A report by the Centers for Disease Control and Prevention found that, of people with active infections, 44% reported no symptoms.

    But the market for over-the-counter tests is risky. Demand for testing has plunged dramatically since the height of the winter surge and may not rebound as more people are vaccinated.

    'You clearly are at risk of missing the market,' said Michael Greeley, co-founder and general partner at Flare Capital Partners, a venture capital firm focused on health care technology.

    But Douglas Bryant, president and CEO of Quidel Corp., remains unfazed, even after the diagnostics manufacturer’s testing demand dropped by about one-third in the past two months.

    "The level of testing for people with symptoms and the 'worried well,' who see others getting tested and think they should, too, is subsiding," Bryant said. "But once we start to get more people vaccinated, the government will move from campaigning to get people vaccinated to saying, 'Please test yourself regularly so we can get back to work.'"

    Quidel, headquartered in San Diego, recently unveiled its latest test, the QuickVue At-Home COVID-19 Test, which takes 10 minutes to detect the coronavirus by homing in on specific proteins, called antigens. The FDA authorized the test for over-the-counter use Wednesday, and Quidel plans to announce retail partners in the coming weeks.

    The FDA said in mid-March it would speed the pipeline for “screening testing,” including at-home covid tests that don’t require consumers to have symptoms or a prescription.

    In February, the Biden administration cut a $232 million deal with Ellume, whose rapid antigen test was authorized by the FDA in December. Paired with an app, the test takes 15 minutes to analyze after a nose swab.

    The Australian company currently ships hundreds of thousands of test kits a week to the U.S. from its factory in Brisbane to large companies and the Department of Defense. It plans to be on the shelves of multiple pharmacies by the second half of the year and in one major retailer in April, said Dr. Sean Parsons, the company’s founder and CEO.

    "We are going as fast as we can possibly go," he said.

    The main holdup for Ellume has been getting enough swabs for its production line. The company is building a factory in the U.S. to reduce international shipping costs and increase production.

    Abbott, which dominates the rapid-test market, said in January it expects to sell 120 million BinaxNOW antigen tests to consumers in the first half of the year. People who take the test now must do so under observation by telemedicine platform eMed. But Abbott received authorization from the FDA this week for an over-the-counter version that won’t require remote observation or a prescription. The test will be available in U.S. stores in the coming weeks, the company said.

    Throughout the pandemic, the government has depended heavily on medical device behemoth Abbott’s testing options. The company’s rapid-diagnostics arm alone has snared $673 million in federal contracts to combat the coronavirus, according to a ProPublica database. This includes bulk purchases made by the Defense Department, the national prison system, Immigration and Customs Enforcement, the State Department and former President Donald Trump's office.

    But antigen tests sometimes report false negatives, particularly among people without symptoms, noted Dr. Jac Dinnes, who co-authored a review of 64 covid test studies. By comparison, polymerase chain reaction (PCR) tests — generally employed by commercial labs — are more sensitive. PCR tests search for the virus’s genetic material over multiple testing cycles, which magnifies what’s in the swab sample, requiring a much smaller viral load for detection.

    Antigen tests are the basis for most at-home screening, but the FDA has also authorized two at-home options — made by Lucira Health and Cue Health — that use molecular processes similar to a PCR test.



    "I always like to tell people that it is as easy to use as toothpaste."


    Still, many experts support the widespread distribution of cheap, rapid tests, even if they aren’t as sensitive as lab-run alternatives, and see a demand. In Germany, the supermarket chain Aldi began selling rapid tests in early March, roughly $30 for a five-pack, and sold out within hours. One recent study found that if a pack of tests was mailed to every household in the U.S. — even assuming that up to 75% would go into the garbage — they would save thousands of lives and avert millions of infections.

    "Don’t let perfect be the enemy of good," said study co-author and Yale University professor A. David Paltiel. "This doesn’t have to work perfectly to make a huge difference."

    Some companies are working on rapid-testing options that more precisely read samples, such as Gauss.

    The Menlo Park, California, health tech company, which before the pandemic created an artificial intelligence-based app to measure surgical blood loss in real time, aims to harness its expertise to improve on the basic antigen test. It took about a week for CEO Siddarth Satish to raise $30 million of venture capital last October.

    Its covid-testing app uses facial recognition software to confirm that test-takers correctly swab their noses. The app provides step-by-step instructions and timers. After 15 minutes, an algorithm based on thousands of sample tests interprets the result — which displays as a colored line, as with a pregnancy test — using the phone’s camera.

    Gauss and Cellex, which manufactures the Gauss tests, await FDA authorization. In the meantime, they have produced more than 1.5 million kits and struck deals with supermarket chain Kroger and e-pharmacy site Truepill to sell them for about $30.

    "A huge part of the accuracy issue with rapid tests is that you have to visually interpret them," Satish said. "Sometimes you get really faint lines, just like with a pregnancy strip, and there’s some guesswork."

    Lucira Health, based in Emeryville, California, uses something called loop-mediated isothermal amplification technology, which is similar to PCR tests in precision. In February, the company went public, raising $153 million largely to fund the manufacturing of its all-in-one testing kit, currently prescribed by doctors across the country. The kit comes with a nose swab and a vial of chemicals analyzed by a hand-held device — taking up to 30 minutes for results.

    Kelly Lewis Brezoczky, Lucira’s executive vice president, envisions the test kit on the shelf in local pharmacies, perched next to the NyQuil. "I always like to tell people that it is as easy to use as toothpaste," she said.

    Subscribe to KHN's free Morning Briefing.


    More Sentinel Stories



    Photo Galleries


    2025 Illinois Marathon Photo Gallery
    A couple of runners found themselves in the wrong race at this year's Illinois Marathon. Over 60 photos from the race that you should see.

    Photos: Sentinel/Clark Brooks